Sucraid

Digestives, Including Enzymes
Enzyme Dietary Supplements

One full measuring scoop supplied by the manufacturer equals 1 mL, and 28 drops from the sacrosidase multiple-dose bottle equals 1 mL. The 1 mL dose is available as a multiple-dose bottle. The 2 mL dose is available as a multiple-dose bottle and a single-use container.
Dilute each 1 mL dose in 60 mL and each 2 mL dose in 120 mL of cold or room temperature water, milk, or infant formula. Do not heat the solution, combine it with hot liquids, or mix or consume with acidic beverages (e.g., fruit juice) because this may reduce the enzyme activity.
Administer approximately half of the dose before the meal or snack and the remainder during the meal or snack.
Storage: Discard the multiple-dose bottle 4 weeks after opening, and rinse the measuring scoop with water after each use.

constipation / Delayed / 3.8-3.8
dehydration / Delayed / 1.9-1.9
wheezing / Rapid / Incidence not known

abdominal pain / Early / 7.7-7.7
vomiting / Early / 5.8-5.8
diarrhea / Early / 3.8-3.8
nausea / Early / 3.8-3.8
insomnia / Early / 1.9-1.9
headache / Early / 1.9-1.9

Sucraid

Rx

Oral enzyme produced as a by-product of the manufacture of baker's yeast
Used for the treatment of sucrase deficiency associated with congenital sucrase-isomaltase deficiency
Due to the potential for hypersensitivity reactions, administer initial doses near a facility that can treat acute hypersensitivity reactions or test for sacrosidase hypersensitivity through skin abrasion testing

2 mL (17,000 international units) or 2 full measuring scoops PO mixed in 120 mL of cool or room temperature water or milk; give with each meal or snack. Administer approximately half of the dosage at the beginning of the meal or snack and the remainder during the meal or snack. Do not mix in or consume with fruit juice.

2 mL (17,000 international units) or 2 full measuring scoops PO mixed in 120 mL of cool or room temperature water or milk; give with each meal or snack. Administer approximately half of the dosage at the beginning of the meal or snack and the remainder during the meal or snack. Do not mix in or consume with fruit juice.

1 mL (8,500 international units) or 1 full measuring scoop PO mixed in 60 mL of cool or room temperature water, milk, or infant formula with each meal or snack. Administer approximately half of the dosage at the beginning of the meal or snack and the remainder during the meal or snack. Do not mix in or consume with fruit juice.

Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.

Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.

Food: (Moderate) Sacrosidase should not be reconstituted or consumed with acidic food, like fruit juice, since the acidity may reduce the enzyme activity.

Sacrosidase/Sucraid Oral Sol: 1mL, 8500U

2 mL PO with each meal or snack.

2 mL PO with each meal or snack.

2 mL PO with each meal or snack.

weighing more than 15 kg: 2 mL PO with each meal or snack.
weighing 15 kg or less: 1 mL PO with each meal or snack.

5 months of age and older: 1 mL PO with each meal or snack.
younger than 5 months of age: Safety and efficacy have not been established.

Sacrosidase hydrolyzes sucrose (a disaccharide) into its component monosaccharides, glucose and fructose. Sacrosidase replaces the endogenous enzyme sucrase (produced in the small intestine) which is necessary for the digestion of sucrose. Administration of sacrosidase to sucrase deficient patients with congenital sucrase-isomaltase deficiency (CSID) resulted in significantly fewer total stools as well as a reduction in overall symptoms.

Sacrosidase is administered orally. In the stomach and intestines, the enzyme is broken down into amino acids and peptides which are then absorbed as nutrients. No further pharmacokinetic information is available.

Animal reproduction studies have not been conducted with sacrosidase. The enzyme is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity; however, sacrosidase should be given during pregnancy only if clearly needed.

Clinical trials examining the use of sacrosidase in breast-feeding women have not been conducted; the exact effects on a nursing infant have not been defined. After ingestion, sacrosidase is broken down in the stomach and intestines, and then the remaining amino acids and peptides are absorbed as nutrients. Adverse effects on a nursing infant are not expected. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.